Scarica l'app Stockscreener
11.05
1.28%
0.14
Precedente Chiudi:
$10.91
Aprire:
$10.91
Volume 24 ore:
169.97K
Relative Volume:
0.63
Capitalizzazione di mercato:
$530.51M
Reddito:
$62.02M
Utile/perdita netta:
$-45.65M
Rapporto P/E:
-12.01
EPS:
-0.92
Flusso di cassa netto:
$-9.60M
1 W Prestazione:
+4.44%
1M Prestazione:
-0.90%
6M Prestazione:
+19.07%
1 anno Prestazione:
+32.81%
Intervallo 1D:
$10.91
$11.17
Intervallo di 1 settimana:
$10.58
$11.44
Portata 52W:
$7.44
$11.82
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Confronta TBPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
11.05 | 530.51M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Iniziato | BTIG Research | Buy |
| 2024-01-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Iniziato | JP Morgan | Overweight |
| 2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Iniziato | Cowen | Outperform |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-29 | Ripresa | Piper Jaffray | Overweight |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-12-21 | Iniziato | Needham | Buy |
| 2016-11-03 | Iniziato | Piper Jaffray | Overweight |
| 2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Iniziato | Guggenheim | Buy |
| 2016-06-20 | Reiterato | Leerink Partners | Outperform |
| 2016-05-12 | Iniziato | Leerink Partners | Outperform |
| 2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Theravance Biopharma (NASDAQ:TBPH) Now Covered by Jones Trading - Defense World
Theravance Biopharma (TBPH) Receives New Analyst Coverage with a Buy Rating | TBPH Stock News - GuruFocus
(TBPH) Proactive Strategies - news.stocktradersdaily.com
Theravance Biopharma (TBPH) Gains Buy Rating with Promising Drug Prospects | TBPH Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance and Mylan settle patent dispute with Eugia Pharma - MSN
theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa
Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha
Theravance BiopharmaTheravance And Mylan Enter Settlement Agreement With EugiaSEC Filing - MarketScreener
Theravance Biopharma Settles Patent Litigation with Eugia - TipRanks
theravance biopharma settles patent litigation with eugia pharma - Investing.com
Theravance Biopharma Sells Remaining Trelegy Royalties to GSK for $225 Million - Global Legal Chronicle
(TBPH) Investment Analysis - news.stocktradersdaily.com
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - sharewise
ProShare Advisors LLC Takes Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLC - Defense World
Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - marketscreener.com
Theravance Biopharma Sells Trelegy Royalty Interest to GSK - TipRanks
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in T - GuruFocus
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - Eagle-Tribune
Ameriprise Financial Inc. Cuts Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Nuveen Asset Management LLC Buys 48,635 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Deutsche Bank AG Purchases 15,608 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Jane Street Group LLC Has $493,000 Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Bank of America Corp DE Increases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - Barchart.com
(TBPH) On The My Stocks Page - news.stocktradersdaily.com
Northern Trust Corp Has $3.67 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance
Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and Ampreloxetine - Investing.com Canada
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by StockNews.com - Defense World
When (TBPH) Moves Investors should Listen - news.stocktradersdaily.com
Theravance Biopharma to Participate in an Upcoming Investor Conf - GuruFocus
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune
Price T Rowe Associates Inc. MD Buys 9,315 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Dimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma Announces Ampreloxetine Presentations at th - GuruFocus
Theravance Biopharma, Inc. Announces Ampreloxetine Presentations At the International MSA Congress - marketscreener.com
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - TradingView
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - Stock Titan
Theravance Biopharma: Promising Future with Strong Product Pipeline and Market Expansion - TipRanks
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights - GuruFocus
Tower Research Capital LLC TRC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - The AM Reporter
Wells Fargo & Company MN Has $204,000 Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Progress Amid Challenges - GuruFocus
Theravance Biopharma Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecast - Investing.com
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):